Engineered yeast synthesizes cancer drug precursors, reducing reliance on endangered Himalayan plant
This digest was compiled by AI from multiple sources — links to the originals are below.
Scientists have engineered common baker's yeast to produce a key chemical precursor for the cancer drugs etoposide and teniposide. The breakthrough offers a sustainable alternative to harvesting the endangered Himalayan mayapple, the traditional source of the compound.
Etoposide Production Challenges
Millions of cancer patients annually rely on etoposide and teniposide for lung, blood, and organ cancers. The current manufacturing process depends on chemical precursors extracted from Podophylloideae plants, notably the endangered Sinopodophyllum hexandrum found in high-altitude Himalayas. The extraction is low-yield and technically complex, creating supply vulnerabilities.
Yeast-Based Precursor Synthesis
Researchers have engineered baker’s yeast (Saccharomyces cerevisiae) to produce a key precursor molecule. The yeast pathway bypasses the need for plant-derived starting materials. The study, published in a recent journal, details the biosynthetic route and optimization steps.
Conservation Implications
Shifting production to yeast fermenters could eliminate the pharmaceutical industry's reliance on S. hexandrum. The plant’s population has been declining due to overharvesting and habitat loss. A viable yeast alternative would conserve the species and stabilize drug supply chains.
What's Next
Further scaling and regulatory approval are required before yeast-derived precursors can enter commercial production. It remains unclear how quickly the new process could be adopted, given entrenched manufacturing practices and the need for large-scale fermentation facilities.
1 source
Engineered yeast synthesizes cancer drug precursors, reducing reliance on endangered Himalayan plant
